• Dimerix signs $1.07 billion licensing deal for DMX-200 in Japan
• ACTION3 Phase 3 trial recruitment completed, Part 2 analysis anticipated in Q3 2025
• Dimerix receives $7.9M R&D Tax Incentive Rebate

During the quarter, Dimerix continued to make significant progress with its lead program, the ACTION3 Phase 3 clinical trial in focal segmental glomerulosclerosis (FSGS), completing the Part 2 recruitment target of 144 patients. The company also announced a development and license agreement with Fuso Pharmaceutical Industries Limited for the commercialization of DMX-200 in FSGS kidney disease in Japan, worth up to ¥10.5 billion (approximately AU$1.07 billion) in upfront, development, and sales milestone payments, plus royalties. This is the third licensing agreement Dimerix has executed for DMX-200 in FSGS, following deals with Advanz Pharma and Taiba. Dimerix ended the quarter with a cash balance of AU$21.11 million and received a AU$7.9 million R&D Tax Incentive Rebate. The company continues to receive strong partnering interest in DMX-200 for unpartnered territories.